Danshen for Health & Longevity
Evidence Review created on 10/18/2026 using AI4L + evidence-mcp / Gemini 4 Argon
Also known as: Salvia miltiorrhiza, Red Sage, Chinese Sage, Chinese Red Sage, Danshen Root, Dan Shen, Tan Shen
Motivation
Danshen (Salvia miltiorrhiza, also known as red sage or Chinese red sage) is a perennial root herb whose vivid red rhizomes contain two distinct families of active plant compounds: water-soluble phenolic acids and fat-soluble red quinone pigments. Health-conscious adults exploring botanical longevity strategies have taken an interest in Danshen because its constituents interact with cellular pathways governing vascular blood flow, oxidative balance, and tissue scarring.
Recorded for over two millennia in traditional Chinese medical texts as a premier botanical for blood circulation, Danshen has transitioned into modern hospital and outpatient practice across East Asia in both oral formulations and intravenous infusions. Researchers in cardiology, nephrology, and urology have conducted clinical trials investigating whether standardized extracts or multi-herb combinations influence blood pressure, cholesterol levels, angina symptoms, kidney filtration, and male urinary function, while clinical pharmacologists have examined how the root alters the breakdown of common prescription medications.
This review examines the human clinical trials, systematic reviews, and preclinical aging studies on Danshen across cardiovascular, renal, and urological domains, alongside its side effect profile, herb-drug interactions, dosing protocols, and quality standards.
Benefits - Risks - Protocol - Conclusion
Recommended Reading
This section curates foundational narrative reviews that provide a high-level overview of Danshen’s phytochemistry, cardiovascular and vascular-aging pharmacology, clinical applications, and herb-drug interactions.
-
Cardiovascular effects of Danshen - Cheng, 2007
Synthesizes the clinical history, cardiovascular mechanisms, therapeutic uses, adverse events, and warfarin interactions of Salvia miltiorrhiza across East Asian and Western medical practice.
-
Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use - Zhou et al., 2005
Details the chemical structures, oral bioavailability, tissue distribution, and clinical pharmacology of Danshen’s hydrophilic phenolic acids and lipophilic tanshinones.
-
Salvia miltiorrhiza: Traditional medicinal uses, chemistry, and pharmacology - Su et al., 2015
Provides a broad ethnopharmacological and chemical overview of over 200 isolated constituents from Salvia miltiorrhiza along with their cardiovascular, neuroprotective, and anti-fibrotic properties.
-
Oxidative Stress and Salvia miltiorrhiza in Aging-Associated Cardiovascular Diseases - Chang et al., 2016
Examines how salvianolic acids and tanshinones modulate reactive oxygen species (ROS, chemically reactive oxygen molecules that damage cells) and endothelial senescence in vascular aging.
-
Salvia miltiorrhiza Roots against Cardiovascular Disease: Consideration of Herb-Drug Interactions - Chen et al., 2017
Reviews the mechanisms by which Danshen constituents induce or inhibit drug-metabolizing enzymes and efflux transporters when co-administered with cardiovascular medications.
Dedicated coverage of Danshen was not found on prioritized longevity platforms (Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension Magazine, and Lifespan.io), as Western longevity commentary focuses primarily on isolated nutraceuticals rather than traditional Chinese botanical roots.
Grokipedia
No Grokipedia article exists for Danshen (Salvia miltiorrhiza).
Examine
-
Summarizes human and preclinical evidence on Salvia miltiorrhiza for cardiovascular health, blood pressure, liver fibrosis, and diabetic complications, while highlighting severe bleeding risks when combined with anticoagulant medications.
ConsumerLab
No dedicated ConsumerLab product review or primary article exists for Danshen (Salvia miltiorrhiza).
Systematic Reviews
This section highlights peer-reviewed systematic reviews and meta-analyses evaluating the clinical efficacy and safety of Danshen preparations across renal, cardiovascular, and cerebrovascular conditions.
-
Pools 21 randomized controlled trials (RCTs, studies randomly assigning participants to treatment or control) showing single-herb Salvia miltiorrhiza improved kidney filtration and endothelial function.
-
Efficacy and Safety of Salvia miltiorrhiza for Treating Chronic Kidney Diseases: A Systematic Review and Meta-Analysis - Zhang et al., 2022
Synthesizes 32 RCTs (2,264 patients) demonstrating that adjunctive Salvia miltiorrhiza improved kidney filtration markers and delayed dialysis initiation without increasing adverse events.
-
Analyzes 93 RCTs (10,208 patients), finding that adjunctive Compound Danshen Dripping Pills (CDDP) improved angina symptoms and cardiac ejection fraction with low-to-moderate certainty.
-
Danshen (Chinese medicinal herb) preparations for acute myocardial infarction - Wu et al., 2008
Cochrane review of 6 trials (2,368 patients) concluding that high-bias evidence does not support mortality reduction from Danshen after acute myocardial infarction.
-
Dan Shen agents for acute ischaemic stroke - Wu et al., 2007
Cochrane review of 6 trials (494 patients) finding that poor methodological quality and absent functional disability data preclude conclusions in acute ischemic stroke.
While these meta-analyses evaluate general trial adverse events, no systematic review on PubMed specifically quantifies Danshen’s principal pharmacological risk: warfarin over-anticoagulation and bleeding.
Mechanism of Action
Danshen (Salvia miltiorrhiza) root contains two bioactive fractions: water-soluble phenolic acids (salvianolic acid B, salvianolic acid A, danshensu, and rosmarinic acid) and fat-soluble diterpenoid quinones (tanshinone IIA, cryptotanshinone, and dihydrotanshinone I) (Zhou et al., 2005). Hydrophilic phenolic acids activate nuclear factor erythroid 2-related factor 2 (Nrf2, an antioxidant transcription factor), elevating superoxide dismutase (SOD, a radical-scavenging enzyme) and glutathione (GSH, the main intracellular antioxidant) (Chang et al., 2016). In endothelium, salvianolic acid B stimulates AMP-activated protein kinase (AMPK, a cellular energy sensor) and sirtuin 1 (SIRT1, a longevity-linked deacetylase), promoting endothelial nitric oxide synthase (eNOS, the vasodilatory nitric oxide enzyme) while blocking vascular calcium channels (Yin et al., 2025). Lipophilic tanshinones inhibit nuclear factor kappa B (NF-κB, an inflammatory signaling complex), suppress transforming growth factor-beta 1 (TGF-β1, a pro-scarring cytokine) and Smad3 (a fibrotic signaling protein), and inhibit platelet aggregation and cyclooxygenase-2 (COX-2, a prostaglandin-forming enzyme) (Su et al., 2015). Competing effects occur in human lipid metabolism: despite preclinical lipid lowering, oral aqueous Danshen can raise human low-density lipoprotein (LDL, atherogenic cholesterol) levels (van Poppel et al., 2015). Both fractions show <5% oral bioavailability, short half-lives (1 to 3 hours for phenolic acids; 3 to 6 hours for tanshinones), hepatic and renal tropism, and clearance via catechol-O-methyltransferase (COMT, a methylation enzyme), uridine diphosphate-glucuronosyltransferases (UGT, conjugation enzymes), and cytochrome P450 3A4 (CYP3A4, the primary drug-oxidizing enzyme), which tanshinones acutely inhibit in gut enterocytes but chronically induce via the pregnane X receptor (PXR, a xenobiotic receptor) (Chen et al., 2017).
Historical Context & Evolution
First recorded around the first century CE in the Shennong Bencao Jing (Divine Farmer’s Classic of Materia Medica), Danshen was classified in the highest (“superior”) tier of traditional Chinese herbs, meaning botanicals suitable for long-term tonic use to invigorate blood circulation, resolve blood stasis, calm the mind, and relieve chest pain (Su et al., 2015). During the Ming Dynasty, Li Shizhen’s Bencao Gangmu (1596) popularized the clinical aphorism that “one herb Danshen possesses the same blood-nourishing and stasis-clearing power as the four-herb Siwu Decoction,” cementing its role in vascular formulas (Cheng, 2007). Modern phytochemical research began in 1934 when Japanese chemists Nakao and Fukushima isolated the red quinone pigments and named them tanshinones, followed in the 1970s and 1980s by Chinese scientists who showed that water-soluble salvianolic acids and danshensu accounted for the vascular activity of traditional aqueous decoctions (Zhou et al., 2005). By the late twentieth century, Chinese manufacturers developed hospital injections and sublingual CDDP, which received approval in China in 1994 and United States Food and Drug Administration (FDA) Investigational New Drug (IND, authorization for human clinical trials) status in 1997 as T89/Dantonic (Zhou et al., 2005; Zhao et al., 2026). Scientific opinion subsequently evolved: whereas early Chinese hospital studies reported near-universal cardiovascular and stroke recovery, rigorous Cochrane reviews in 2007 and 2008 identified randomization flaws and no mortality reduction (Wu et al., 2007; Wu et al., 2008), prompting recent double-blind placebo-controlled trials of standardized oral extracts (van Poppel et al., 2015; Shin et al., 2024).
Expected Benefits
High 🟩 🟩 🟩
No benefit reaches High: human clinical endpoints and validated surrogates for oral single-herb Danshen have not been replicated across multiple independent research groups, as replicated positive trials tested multi-herb co-formulations or intravenous hospital infusions.
Medium 🟩 🟩
Lower Urinary Tract Symptoms and Erectile Function ⭕️ Not Central to Health & Longevity
This benefit addresses male urological and sexual function rather than systemic longevity. Standardized Salvia miltiorrhiza root extract suppresses prostatic inflammation and androgen receptor signaling via Nrf2 activation and NF-κB inhibition without inhibiting 5-alpha-reductase (the testosterone-to-dihydrotestosterone enzyme). In a 12-week multicenter, double-blind, placebo-controlled RCT of 136 men with lower urinary tract symptoms, oral Salvia miltiorrhiza extract (SAGX, 400 or 800 mg/day) significantly improved urinary symptoms and erectile function versus placebo (Shin et al., 2024). Limitations include one research consortium, industry co-authorship, and unchanged testosterone or prostate-specific antigen (PSA, a prostate marker).
Magnitude: Total International Prostate Symptom Score (IPSS, a validated 0-to-35 urinary symptom severity scale) decreased by 4.40 points with 400 mg/day and 5.03 points with 800 mg/day over 12 weeks (both statistically significant versus placebo across all voiding and storage subscores, p < 0.05), alongside a statistically significant increase in International Index of Erectile Function (IIEF, a validated male erectile performance scale) at 400 mg/day versus placebo (Shin et al., 2024).
Low 🟩
Blood Pressure Reduction ⚠️ Conflicted
Danshen promotes vasodilation via eNOS and calcium channel blockade. Oral Fufang Danshen (Yang et al., 2012, N=55) and intravenous Danshen (Li et al., 2025, N=320) lowered blood pressure, whereas oral Danshen (van Poppel et al., 2015, N=20) had no effect. Net evidence shows single-herb oral Danshen is ineffective.
Magnitude: Oral Fufang Danshen lowered systolic blood pressure by 9.6 millimeters of mercury (mmHg) more than placebo (13.8 mmHg vs. 4.2 mmHg reduction, p = 0.005) (Yang et al., 2012), whereas 3 g daily of oral single-herb Danshen extract produced no significant difference in 24-hour ambulatory blood pressure compared with placebo (138/84 mmHg vs. 136/87 mmHg) (van Poppel et al., 2015).
Stable Angina Symptom Relief and Myocardial Perfusion
Danshen dilates coronary vessels and inhibits platelets. A 93-RCT meta-analysis (Zhao et al., 2026, N=10,208) improved angina and electrocardiogram (ECG, cardiac electrical recording) ischemia, while an intravenous RCT (Lyu et al., 2021, N=135) improved symptom scores and platelet reactivity. Evidence is indirect because trials tested multi-herb CDDP or intravenous infusions.
Magnitude: Adjunctive CDDP increased angina symptom improvement relative risk (RR, the ratio of outcome probability between groups) to 1.26 (95% confidence interval [CI, the range of plausible true values] 1.19-1.33), ECG improvement to RR 1.34 (95% CI 1.19-1.51), and left ventricular ejection fraction (LVEF, percentage of blood pumped per heartbeat) by a standardized mean difference (SMD, effect size in standard deviation units) of 1.30 (95% CI 0.24-2.37) versus conventional therapy alone (Zhao et al., 2026).
Renal Function and Endothelial Preservation in Kidney Disease
Phenolic acids suppress renal TGF-β1 fibrosis and vascular inflammation. Meta-analyses in chronic (Zhang et al., 2022, 32 RCTs, N=2,264) and diabetic kidney disease (Zheng et al., 2025, 21 RCTs, N=1,970) improved filtration and flow-mediated dilation (FMD, ultrasound arterial dilation). Evidence is indirect because trials primarily used hospital intravenous infusions.
Magnitude: Adjunctive Salvia miltiorrhiza preparations increased estimated glomerular filtration rate (eGFR, blood-based kidney filtration calculation) by SMD 0.56 (95% CI 0.30-0.83), reduced serum creatinine by SMD -0.60 (95% CI -0.79 to -0.41), lowered 24-hour proteinuria by SMD -0.70 (95% CI -1.21 to -0.19), and reduced dialysis initiation by log RR 0.43 (95% CI 0.23-0.81) compared with conventional therapy alone (Zhang et al., 2022).
Acute Ischemic Stroke Neurological Recovery ⚠️ Conflicted
Danshen is used in China for cerebral microcirculation. A Cochrane review (Wu et al., 2007, 6 RCTs, N=494) noted short-term score gains, but an active-comparator review (Sze et al., 2005, 11 RCTs) found worse recovery with Danshen. Net evidence shows no reliable benefit due to bias and active-control inferiority.
Magnitude: Low-quality trials reported a short-term neurological improvement odds ratio (OR, the ratio of outcome odds between groups) of 3.02 (95% CI 1.73-5.26) (Wu et al., 2007), whereas head-to-head trials showed Danshen produced significantly lower improvement odds than buflomedil (OR 0.27, 95% CI 0.12-0.61) or naloxone (OR 0.16, 95% CI 0.07-0.40) (Sze et al., 2005).
Acute Myocardial Infarction Survival and Recovery ⚠️ Conflicted
Danshen is administered in Chinese hospitals to limit myocardial reperfusion injury. A Cochrane review (Wu et al., 2008, 6 studies, N=2,368) found mortality reductions only in quasi-randomized cohorts, while the sole genuine RCT showed no survival benefit. Net evidence shows no reliable mortality reduction after acute myocardial infarction.
Magnitude: In the only genuine randomized trial, total mortality did not differ significantly between adjunctive Danshen and control (Peto OR 0.55, 95% CI 0.23-1.32), whereas lower-quality quasi-randomized trials reported a pooled Peto OR of 0.46 (95% CI 0.28-0.75) (Wu et al., 2008).
Acute Mountain Sickness Prevention ⚠️ Conflicted ⭕️ Not Central to Health & Longevity
This outcome targets short-term altitude adaptation rather than longevity. Although Chinese reports suggested hypoxia tolerance from CDDP, a Phase 2 RCT (Schober et al., 2023, N=132) testing oral AR36 (T89/CDDP) at 3,800 meters found no effect. Net evidence indicates oral CDDP fails to prevent acute mountain sickness.
Magnitude: Mean Lake Louise Acute Mountain Sickness scores did not differ significantly between low-dose AR36 (4.42, p = 0.462), high-dose AR36 (3.50, p = 0.574), and placebo (4.03), with acute mountain sickness incidence rates of 61.1%, 55.3%, and 66.7% respectively (p = 0.66) (Schober et al., 2023).
Speculative 🟨
Systemic Antioxidant Enzyme Upregulation
In 62 diabetic coronary heart disease (CHD, coronary atherosclerosis) patients (Qian et al., 2012), oral Danshen lowered malondialdehyde (MDA, lipid peroxide marker) and raised SOD and GSH. These unvalidated biomarkers lack clinical outcome validation.
Lifespan Extension and Amyloid-Beta Neuroprotection
Danshen extracts inhibited amyloid-beta aggregation, extended Drosophila melanogaster lifespan (Tan et al., 2021; Go et al., 2024), and reduced Caenorhabditis elegans paralysis (Yuen et al., 2021). No human trials exist.
Tissue Senescence Attenuation and Hepatic Longevity
In aged mice, tanshinone IIA and Danshen slowed liver aging via estrogen-related receptor gamma (ESRRG, nuclear receptor)/cytochrome P450 2E1 (CYP2E1, oxidase) (Liu et al., 2024) and AMPK/SIRT1 (Yin et al., 2025). Human data are lacking.
Cutaneous Photoprotection and Dermal Matrix Preservation
In ultraviolet-irradiated mice, salvianolic acids prevented collagen loss via Nrf2 (Sun et al., 2024) and inhibited cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING, DNA-sensing inflammation pathway) (Zuo et al., 2024). No human trials exist.
Benefit-Modifying Factors
- Genetic polymorphisms: Variants in CYP3A4, COMT, and multidrug resistance protein 1 (MDR1, also termed ABCB1, encoding the intestinal efflux pump P-glycoprotein [P-gp]) alter systemic exposure to tanshinones and salvianolic acids, modifying individual vascular and antiplatelet responses (Chen et al., 2017).
- Baseline biomarker levels: Improvements in eGFR, proteinuria, and antioxidant enzymes occur primarily in individuals with elevated baseline creatinine, albuminuria, or oxidative stress (Zheng et al., 2025), whereas mildly hyperlipidemic outpatients without renal disease show negligible FMD changes (van Poppel et al., 2015).
- Sex-based differences: Urological and erectile improvements from standardized Salvia miltiorrhiza extract (SAGX) are established exclusively in men (Shin et al., 2024), while cardiovascular and renal meta-analyses demonstrate comparable microvascular responses across men and women (Zhang et al., 2022).
- Pre-existing health conditions: Patients with diabetic kidney disease (Zheng et al., 2025), stable angina (Zhao et al., 2026), or uncontrolled hypertension (Yang et al., 2012) show stronger microvascular responses than healthy adults ascending to high altitude (Schober et al., 2023).
- Age-related considerations: Older adults (60 to 80 years) exhibit higher vascular stiffness, prostatic enlargement, and reduced kidney filtration, increasing responsiveness to microvascular and lower urinary tract symptoms (LUTS, prostatic voiding symptoms) protocols (Shin et al., 2024) while elevating polypharmacy risks (Chen et al., 2017).
- Formulation and route of administration: Low oral bioavailability of salvianolic acid B (<5%) explains why intravenous infusions and borneol-enhanced multi-herb formulas achieve stronger blood pressure and lipid reductions (Li et al., 2025) than oral single-herb water extracts (van Poppel et al., 2015).
Potential Risks & Side Effects
High 🟥 🟥 🟥
Subtherapeutic Exposure of Co-Administered Medications
Repeated oral administration of Danshen extracts activates PXR, inducing intestinal and hepatic CYP3A4, carboxylesterase 1 (CES1, a hepatic prodrug-cleaving esterase), P-gp, and breast cancer resistance protein (BCRP, an intestinal efflux transporter). Controlled human crossover trials from three independent research groups (Qiu et al., 2013; Zhou et al., 2018; Yang et al., 2019) demonstrate that 7 to 14 days of oral Salvia miltiorrhiza accelerates systemic drug clearance and blunts antiplatelet or lipid-lowering efficacy. Enzyme induction resolves within 1 to 2 weeks after cessation.
Magnitude: Compared with drug administration alone in healthy volunteers, oral Danshen decreased midazolam area under the plasma concentration-time curve (AUC, total systemic drug exposure over time) by 79.9% and maximum plasma concentration (Cmax, peak blood drug concentration) by 66.6% (Qiu et al., 2013), reduced clopidogrel AUC by 50.3% and Cmax by 41.7% (Zhou et al., 2018), lowered fexofenadine AUC by 37.2% (Qiu et al., 2014), and reduced rosuvastatin Cmax by 26.85% and AUC by 19.43% (Yang et al., 2019).
Medium 🟥 🟥
No risk reaches Medium: single-trial human harms of oral single-herb Danshen such as LDL cholesterol elevation are conflicted by larger randomized trials showing neutral or reduced lipid levels, and other documented human harms derive from case reports or indirect formulations graded Low.
Low 🟥
Low-Density Lipoprotein Cholesterol Elevation ⚠️ Conflicted
In 20 hyperlipidemic outpatients (van Poppel et al., 2015), 3 g/day of oral Danshen raised LDL. Conversely, an oral RCT (Qian et al., 2012, N=62) found unchanged lipids, and intravenous Danshen (Li et al., 2025, N=320) lowered LDL. Net evidence shows oral aqueous Danshen can raise LDL in hyperlipidemia.
Magnitude: Fasting serum LDL cholesterol increased by 0.30 millimoles per liter (mmol/L) on oral Danshen compared with placebo (3.82 ± 0.14 mmol/L vs. 3.52 ± 0.16 mmol/L, p < 0.05) (van Poppel et al., 2015), whereas intravenous Danshen lowered LDL cholesterol by 10.7% versus placebo (p < 0.05) (Li et al., 2025).
Warfarin Potentiation and Severe Hemorrhage ⚠️ Conflicted
Danshen inhibits platelets and cytochrome P450 2C9 (CYP2C9, S-warfarin-clearing enzyme). Case reports (Chan, 2001; Izzat et al., 1998) and a volunteer trial (Zhang et al., 2020, N=14) show coagulopathy (impaired clotting), whereas an atrial fibrillation cohort (Lv et al., 2017) found minimal CDDP effect. Net evidence confirms bleeding risk.
Magnitude: Case reports document international normalized ratio (INR, standardized blood clotting ratio) spikes above 5.0 to 8.4 and prothrombin time (PT, blood clotting time) exceeding 60 seconds with pleural or gastrointestinal bleeding (no control group) (Chan, 2001; Izzat et al., 1998).
Mild Gastrointestinal Discomfort and Vasodilatory Headache ⚠️ Conflicted
Oral Danshen and borneol formulas can irritate gastric mucosa and cause headache (Jia & Leung, 2017). However, meta-analyses (Zhao et al., 2026, 93 RCTs; Zheng et al., 2025, 21 RCTs) found no excess adverse events and fewer headaches than nitrates. Net evidence shows placebo-like gastrointestinal symptom rates.
Magnitude: Overall adverse event rates did not differ significantly from control in diabetic kidney disease trials (Zheng et al., 2025) and were significantly lower with CDDP than with isosorbide dinitrate in 60 angina RCTs (OR 0.23, 95% CI 0.18-0.29; 2.4% vs. 9.7% event rate) (Jia & Leung, 2017).
Serum Digoxin Immunoassay Interference
Lipophilic tanshinones possess a steroid-like ring structure that cross-reacts with anti-digoxin antibodies in clinical laboratory assays (Wahed & Dasgupta, 2001). Human serum studies show falsely elevated or depressed digoxin readings on fluorescence polarization and microparticle enzyme immunoassays (Datta & Dasgupta, 2002). Chemiluminescent assays prevent this analytical error.
Magnitude: Direction and conditions established in human serum immunoassay studies (significant false positive and false negative bias in fluorescence polarization and microparticle enzyme assays at therapeutic serum concentrations, eliminated by chemiluminescent immunoassay); the literature reports no clinical trial between-group outcome figure (Datta & Dasgupta, 2002).
Cutaneous Hypersensitivity and Borneol-Related Methemoglobinemia
Reviews (Su et al., 2015; Zhang et al., 2022) note rare pruritus (itching), urticaria (hives), and reversible thrombocytopenia (low platelets). Anaphylactoid reactions occur primarily with intravenous injections, while surveillance linked multi-herb CDDP to rare methemoglobinemia (oxidized hemoglobin) from synthetic borneol (Cheng, 2007). Single-herb oral extracts lack borneol toxicity.
Magnitude: Not quantified in available studies. Controlled trials of oral single-herb Danshen report zero cases of anaphylaxis or methemoglobinemia, with hypersensitivity and hematologic events documented only in isolated case reports and post-marketing pharmacovigilance (Cheng, 2007; Su et al., 2015).
Speculative 🟨
Embryo-Fetal Resorption and Uteroplacental Perfusion Alteration
Traditional Chinese pharmacopeias contraindicate Danshen during pregnancy because vasoactive and antiplatelet constituents alter uteroplacental blood flow and may increase embryo-fetal resorption in rodent models (Zhou et al., 2005). No controlled human pregnancy studies exist.
Supratherapeutic Hepatic Cytochrome Hypertrophy
Chronic rodent toxicology studies confirm wide safety margins for aqueous Danshen extracts. However, concentrated lipophilic tanshinones at supratherapeutic doses in rats induce mild hepatocellular hypertrophy via constitutive PXR activation (Chen et al., 2017).
Risk-Modifying Factors
- Genetic polymorphisms: Carriers of the microsomal epoxide hydrolase 1 (EPHX1, hepatic vitamin K epoxide-regulating enzyme) rs2292566 A/A genotype exhibit heightened warfarin sensitivity and suppressed vitamin K epoxide reductase (VKOR, warfarin’s target enzyme) when taking Danshen (Chen et al., 2023).
- Baseline biomarker levels: Elevated baseline fasting LDL cholesterol (above 3.5 mmol/L) or borderline low platelet counts predispose individuals to atherogenic lipid elevation (van Poppel et al., 2015) or symptomatic bruising and thrombocytopenia during supplementation (Cheng, 2007).
- Sex-based differences: Menstruating and pregnant women face elevated risks of menorrhagia (heavy menstrual bleeding) or uteroplacental bleeding from Danshen’s antiplatelet and COX-2 inhibitory actions (Zhou et al., 2005), whereas pharmacokinetic enzyme induction occurs similarly in both sexes.
- Pre-existing health conditions: Peptic ulcer disease, hemorrhagic diathesis (bleeding tendency), hepatic impairment, or atrial fibrillation requiring anticoagulation markedly increase gastrointestinal irritation and severe hemorrhage risk (Chan, 2001; Zhang et al., 2020).
- Age-related considerations: Older adults frequently manage cardiovascular polypharmacy (statins, clopidogrel, calcium channel blockers, digoxin, or anticoagulants), multiplying CYP3A4, CES1, and P-gp interaction risks and digoxin assay errors (Chen et al., 2017).
- Route and co-formulation: Intravenous hospital injections carry substantially higher anaphylactoid risk than oral capsules (Su et al., 2015), while multi-herb CDDP adds synthetic borneol, increasing gastric burning and methemoglobinemia risk (Jia & Leung, 2017).
Key Interactions & Contraindications
- Vitamin K antagonists (warfarin, acenocoumarol): Contraindication; causes hemorrhage and INR spikes >5.0 to 8.4 (Chan, 2001; Izzat et al., 1998). Danshen-Gegen lowered 7-hydroxywarfarin AUC (Zhang et al., 2020), while CDDP altered warfarin in EPHX1 A/A carriers (Lv et al., 2017; Chen et al., 2023).
- Thienopyridine antiplatelets (clopidogrel, prasugrel): Major interaction (avoid); attenuates antiplatelet protection and risks thrombosis. Seven days of oral Danshen induced CES1 and CYP3A4 in 20 volunteers, reducing clopidogrel AUC by 50.3% and Cmax by 41.7% (Zhou et al., 2018). Concurrent use is avoided.
- CYP3A4 substrates (midazolam, amlodipine, cyclosporine, tacrolimus): Major interaction (monitor or avoid); alters drug levels. Single-dose Danshen raised midazolam Cmax by 87% (Qiu et al., 2010), whereas 10 to 14 days reduced midazolam AUC by 79.9% and Cmax by 66.6% (Qiu et al., 2013).
- P-gp substrates (fexofenadine, digoxin, rivaroxaban, apixaban): Moderate-to-major interaction (avoid with direct oral anticoagulants; monitor others); lowers drug levels. Ten days of ethanol Danshen extract induced intestinal P-gp in 12 men, reducing over-the-counter fexofenadine AUC by 37.2% and Cmax by 27.4% (Qiu et al., 2014).
- BCRP and organic anion transporting polypeptide (OATP, uptake transporters) substrates (rosuvastatin, atorvastatin): Moderate interaction (monitor); lowers statin absorption. Oral Tanjin (Salvia miltiorrhiza) induced gut BCRP in 6 men, reducing rosuvastatin Cmax by 26.85% and AUC by 19.43% (Yang et al., 2019). Dose separation applies.
- Over-the-counter salicylates and nonsteroidal anti-inflammatory drugs (NSAIDs, pain relievers like aspirin, ibuprofen, naproxen): Moderate interaction (caution); increases bleeding risk. Co-administering Danshen-Gegen with aspirin in 14 volunteers raised aspirin AUC and synergistically inhibited COX-2 and thromboxane B2 (Zhang et al., 2020). Monitoring for bruising applies.
- Antiplatelet and hypotensive supplements (garlic, Ginkgo biloba, Panax ginseng, nattokinase, omega-3 fatty acids): Caution (theoretical); may additively prolong bleeding time or lower blood pressure via overlapping platelet and nitric oxide pathways (Chen et al., 2017). Staggered initiation and monitoring for bruising apply.
- Clinical laboratory digoxin immunoassays: Diagnostic interaction (monitor); causes false digoxin toxicity or underdosing. Tanshinones cross-react with fluorescence polarization and microparticle enzyme assays (Wahed & Dasgupta, 2001), which is mitigated by using chemiluminescent immunoassays or protein-free ultrafiltrate digoxin testing (Datta & Dasgupta, 2002).
- Cytochrome P450 1A2 (CYP1A2, methylxanthine-clearing enzyme) substrates (theophylline, caffeine): No clinical interaction. Despite in vitro CYP1A2 inhibition by tanshinones, a crossover trial in 12 volunteers showed 14 days of oral Danshen tablets did not alter theophylline Cmax, half-life, or clearance (Qiu et al., 2008).
Populations who should avoid Danshen:
- Patients taking anticoagulants or clopidogrel: Individuals prescribed warfarin, direct oral anticoagulants (rivaroxaban, apixaban, dabigatran), or clopidogrel, due to severe bleeding risk or 50.3% reduced clopidogrel exposure (Chan, 2001; Zhou et al., 2018).
- Patients with bleeding disorders or prior cerebral hemorrhage: Individuals with hemorrhagic diathesis, thrombocytopenia, active peptic ulceration, or a history of cerebral hemorrhage, per Phase 3 T89 trial exclusion criteria (NCT01659580).
- Patients with acute unstable cardiovascular conditions: Individuals with acute coronary syndrome within the prior 2 months, coronary revascularization within 6 months, decompensated heart failure, or severe uncontrolled hypertension (seated systolic blood pressure > 180 mmHg or diastolic > 110 mmHg) (NCT01659580).
- Perioperative and surgical patients: Individuals undergoing elective surgery, dental extraction, or invasive procedures within 14 days, due to platelet inhibition and CYP3A4/P-gp enzyme induction (Qiu et al., 2013; NCT01659580).
- Pregnant or lactating women: Excluded from all clinical trials (NCT01659580) and contraindicated in traditional pharmacopeias due to vasoactive uteroplacental effects (Zhou et al., 2005).
Risk Mitigation Strategies
Doses, washout intervals, and timings below follow common clinical practice unless cited.
- Anticoagulant and clopidogrel exclusion: Excluding concurrent warfarin or clopidogrel prevents life-threatening coagulopathy (INR > 5.0) (Chan, 2001) and subtherapeutic clopidogrel bioactivation (-50.3% AUC) (Zhou et al., 2018).
- Fourteen-day pre-surgical washout: Stopping Danshen at least 14 days before surgery or dental procedures (NCT01659580) prevents perioperative bleeding and allows induced CYP3A4 and P-gp activity to normalize (Qiu et al., 2013).
- Postprandial administration: Taking oral Danshen preparations 15 to 30 minutes after meals rather than fasting mitigates epigastric discomfort, dyspepsia (indigestion), and nausea (Jia & Leung, 2017).
- Borneol-free single-herb selection: Using standardized single-herb Salvia miltiorrhiza root extracts rather than synthetic borneol-containing compound formulas eliminates borneol-induced gastric irritation and methemoglobinemia risk (Cheng, 2007; Zhao et al., 2026).
- Fasting lipid surveillance and stopping threshold: Re-measuring fasting LDL cholesterol after 4 to 8 weeks and stopping use if LDL rises by >=0.30 mmol/L prevents atherogenic lipid progression (van Poppel et al., 2015).
- Chemiluminescent digoxin monitoring: Utilizing chemiluminescent immunoassays or protein-free ultrafiltrate testing in digoxin-treated patients prevents tanshinone cross-reactivity from causing false digoxin toxicity or underdosing (Datta & Dasgupta, 2002).
Therapeutic Protocol
Timing, titration, and cycling parameters without a specific citation below reflect common integrative practice.
- Standardized root extract (urological protocol): For male LUTS and erectile function, clinical trials administer 400 or 800 mg/day of oral SAGX extract for 12 weeks (Shin et al., 2024).
- Hydrophilic aqueous extract (cardiometabolic protocol): Outpatient trials evaluating antioxidant enzymes and blood pressure administer 1,000 mg twice daily (Yang et al., 2012) or three times daily (2 to 3 g/day) of aqueous extract (van Poppel et al., 2015).
- Pharmacopeial decoction and multi-herb regimens: The Chinese Pharmacopoeia specifies 10 to 15 g/day of dried root decoction (Zhou et al., 2005), while integrative cardiology uses 270 mg (10 dripping units) of CDDP three times daily (Zhao et al., 2026).
- Half-life and split-dose schedule: Because salvianolic acid B and danshensu exhibit short human elimination half-lives of 1 to 3 hours (and tanshinones 3 to 6 hours), protocols split daily intake into two or three doses (Zhou et al., 2005).
- Optimal time of day: Doses are taken with morning and evening meals (plus midday for thrice-daily regimens) to reduce gastric irritation and enhance micellar absorption of fat-soluble tanshinones (Zhou et al., 2005).
- Genetic polymorphisms: Carriers of the EPHX1 rs2292566 A/A variant (Chen et al., 2023) or altered CYP3A4 and MDR1 genotypes (Qiu et al., 2013; Qiu et al., 2014) warrant lower doses (400 mg/day) and strict avoidance of interacting drugs.
- Sex-based differences: Men targeting LUTS and erectile function respond equally well to 400 mg/day and 800 mg/day of SAGX (Shin et al., 2024), whereas menstruating women typically pause antiplatelet extracts during heavy menses.
- Age-related considerations: In adults over 65 years, protocols start at the lower clinical dose (400 mg/day standardized extract) to account for reduced hepatic clearance and higher rates of concurrent cardiovascular medication use (Chen et al., 2017).
- Baseline biomarker levels: Baseline fasting LDL cholesterol above 3.5 mmol/L favors lower-dose lipophilic-standardized extracts (400 mg/day) over high-dose aqueous extracts (3 g/day), which raised LDL in hyperlipidemic adults (van Poppel et al., 2015).
- Pre-existing health conditions: Diabetic CHD and chronic kidney disease protocols apply hydrophilic salvianolic acid-standardized preparations over 4 to 24 weeks alongside conventional care (Qian et al., 2012; Zhang et al., 2022), while bleeding disorders preclude use.
Discontinuation & Cycling
- Short-term versus lifelong duration: Controlled human trials evaluate oral Danshen over finite 4-to-24-week periods (van Poppel et al., 2015; Shin et al., 2024; Zhao et al., 2026). Continuous lifelong supplementation lacks long-term human safety or outcome validation.
- Cycling to limit enzyme induction: Because 10 to 14 days of lipophilic Danshen induces CYP3A4 by 5-fold and P-gp by 2-fold (Qiu et al., 2013; Qiu et al., 2014), integrative protocols use 8-to-12-week cycles followed by a 2-to-4-week washout.
- Absence of withdrawal syndrome: Human clinical trials report no physiological dependence, withdrawal symptoms, or rebound blood pressure elevation following abrupt cessation of oral single-herb Danshen extracts (Yang et al., 2012; van Poppel et al., 2015).
- Tapering in stable angina: When oral Danshen preparations are used as an add-on for chronic stable angina, gradual tapering over 1 to 2 weeks while maintaining baseline anti-anginal pharmacotherapy prevents abrupt symptom recurrence (Jia & Leung, 2017).
- Pre-operative and medication washout: Complete cessation at least 14 days before surgery or before initiating narrow-therapeutic-index CYP3A4, P-gp, or anticoagulant medications allows platelet aggregation and hepatic enzyme expression to return to baseline (Chen et al., 2017).
Sourcing and Quality
- Dual chemical marker standardization: High-grade extracts specify dual standardization by high-performance liquid chromatography (HPLC, chemical separation and quantification) meeting Chinese Pharmacopoeia or United States Pharmacopeia (USP, supplement quality compendium) benchmarks: >=3.0% salvianolic acid B and >=0.25% tanshinones (Su et al., 2015).
- Botanical species authentication: Commercial roots are frequently substituted with lower-cost regional species such as Salvia przewalskii, Salvia yunnanensis, or Salvia bowleyana (Zhou et al., 2005). DNA barcoding or thin-layer chromatography confirms authentic Salvia miltiorrhiza Bunge root.
- Third-party contaminant testing: Because deep-rooted Salvia miltiorrhiza bioaccumulates soil heavy metals, reputable suppliers manufacture under Good Manufacturing Practice (GMP, regulatory batch quality standards) and provide Certificates of Analysis confirming lead, cadmium, arsenic, mercury, and pesticides below USP limits.
- Single-herb versus compound formulation clarity: Ingredient panels distinguish pure Salvia miltiorrhiza root extract (such as SAGX or 5:1 single-herb granules from PuraPharm, Sun Ten, or KPC) from multi-herb “Fufang” formulas (such as Tasly CDDP) containing Panax notoginseng and synthetic borneol (Zhao et al., 2026).
- Photothermal and moisture protection: Salvianolic acid B undergoes rapid hydrolytic degradation in heat and humidity, while tanshinone IIA is photosensitive (Zhou et al., 2005). Quality preparations use opaque blister packs or amber glass bottles stored below 25 degrees Celsius.
Practical Considerations
- Time to effect: CYP3A4 and P-gp induction emerges in 7 to 14 days (Qiu et al., 2013), MDA declines by 30 days and SOD rises by 60 days (Qian et al., 2012), and IPSS responses require 8 to 12 weeks (Shin et al., 2024).
- Common pitfalls: Consumers frequently confuse single-herb Danshen root capsules with multi-herb CDDP containing synthetic borneol, overlook major interactions with statins or clopidogrel (Zhou et al., 2018; Yang et al., 2019), or assume hospital intravenous trial results apply equally to low-bioavailability oral capsules.
- Regulatory status: In the United States and European Union, oral Danshen is sold as an over-the-counter supplement without FDA disease approval (though T89 holds FDA IND status for Phase 3 angina trials: NCT03789552), whereas China regulates standardized preparations as medicines (Zhou et al., 2005).
- Cost and accessibility: Standardized oral Salvia miltiorrhiza capsules and concentrated root extract granules are widely accessible online and through traditional Chinese medicine dispensaries for $15 to $45 per month, making cost rarely a barrier.
Interaction with Foundational Habits
- Sleep: Indirectly potentiating in men with nocturia (nighttime urination); neutral on core sleep architecture. Danshen contains no central nervous system stimulants. In older men with LUTS, 400 to 800 mg daily of oral Salvia miltiorrhiza extract (SAGX) significantly reduced nighttime voiding frequency (Shin et al., 2024), reducing nocturnal awakenings without daytime sedation.
- Nutrition: Directly potentiating for absorption with dietary fat; potentially additive with antiplatelet foods. Administering lipophilic tanshinone extracts with fat-containing meals enhances micellar solubilization and intestinal absorption (Zhou et al., 2005). Conversely, high dietary intake of concentrated garlic, ginger, or omega-3 oils may additively inhibit platelet aggregation (Chen et al., 2017).
- Exercise: Neutral to non-potentiating in healthy adults; complementary in vascular disease. Although aerobic exercise and salvianolic acids both activate AMPK and eNOS (Chang et al., 2016), a Phase 2 RCT in 132 healthy adults ascending to 3,800 meters found oral AR36 (T89/CDDP) failed to reduce acute mountain sickness symptoms (Schober et al., 2023).
- Stress management: Indirectly complementary via autonomic and vascular tone modulation. Sympathetic activation elevates heart rate, blood pressure, and vascular oxidative stress. In patients with uncontrolled mild-to-moderate hypertension, 12 weeks of oral Fufang Danshen (1,000 mg twice daily) lowered resting pulse rate by 3.2 beats per minute alongside systolic blood pressure (Yang et al., 2012).
Monitoring Protocol & Defining Success
Before starting oral Danshen supplementation, baseline laboratory testing establishes lipid, vascular, hematologic, and renal reference points to verify safety and quantify subsequent physiological changes. Baseline assessment includes a fasting lipid panel, seated or 24-hour ambulatory blood pressure, complete blood count (CBC, a blood panel measuring red cells, white cells, and platelets), PT/INR, serum creatinine with eGFR, and IPSS/IIEF symptom scores.
| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| Fasting LDL Cholesterol | < 2.6 mmol/L (< 100 mg/dL, Adult Treatment Panel III guideline target) | Safety check and conflicted efficacy marker: oral aqueous Danshen raised LDL by 0.30 mmol/L in hyperlipidemic adults (van Poppel et al., 2015). | Standard reference range: < 3.4 mmol/L (< 130 mg/dL); target cited in van Poppel et al., 2015. Morning draw after a 12-hour fast; cessation threshold is an LDL rise >= 0.30 mmol/L. |
| Seated or 24-Hour Ambulatory Blood Pressure | < 130/80 mmHg (hypertension treatment threshold, Yang et al. trial) | Expected efficacy marker: tracks vascular response in mild-to-moderate hypertension (Yang et al., 2012). | Standard reference range: < 120/80 mmHg; threshold cited in Yang et al., 2012. Measured seated after 5 minutes of rest at the same morning timepoint. |
| eGFR and Serum Creatinine | >= 90 mL/min/1.73 m² (standard reference range) | Expected efficacy and safety marker: tracks renal filtration preservation in kidney disease (Zhang et al., 2022). | Paired with morning spot urine albumin-to-creatinine ratio; heavy exercise is avoided 24 hours prior. |
| Platelet Count (via CBC) and PT/INR | Platelets 150-450 x 10⁹/L; INR 0.8-1.2 (standard reference range) | Safety check: detects rare reversible thrombocytopenia (Cheng, 2007) or coagulopathy (Chan, 2001). | Cessation threshold is a platelet count below 150 x 10⁹/L or unexplained bruising. |
| IPSS and IIEF Questionnaires | No established target; tracks reduction in IPSS and increase in IIEF from individual baseline (Shin et al., 2024) | Expected efficacy marker: quantifies LUTS relief and erectile function in men (Shin et al., 2024). | Self-administered at baseline, 4 weeks, and 12 weeks. |
Ongoing monitoring re-evaluates blood pressure and qualitative tolerance at 2 to 4 weeks, repeats fasting LDL cholesterol, CBC, and renal panels at 4 to 8 weeks, and assesses full clinical efficacy at 12 weeks, repeating labs every 6 months during cyclical use.
- Urinary symptoms: Nocturia frequency and bladder emptying (Shin et al., 2024).
- Chest comfort: Exertional chest tightness and nitroglycerin use (Zhao et al., 2026).
- Bleeding and digestion: Bruising, epistaxis (nosebleeds), or postprandial dyspepsia (Chan, 2001).
Emerging Research
- FDA Phase 3 T89 Stable Angina Outcome Trial (NCT03789552): Recruiting 765 patients (estimated completion March 2027) to test whether oral T89 (CDDP) improves Day 57 treadmill exercise duration on the Standard Bruce Protocol. Positive results would establish FDA-grade anti-anginal efficacy; null results would challenge prior unblinded Chinese angina meta-analyses (Zhao et al., 2026).
- Diabetic Microvascular Angina Phase 4 Trial (NCT06727890): Not yet recruiting (162 patients, estimated completion June 2027), evaluating 12-month coronary flow reserve via three-dimensional echocardiography with CDDP. Positive findings would support long-term microvascular remodeling in diabetes, whereas null findings would indicate symptom relief does not alter structural coronary reserve.
- Unpublished Completed Phase 3 T89 Trials (NCT01659580; NCT04993729): Both the 1,004-patient Phase 3 angina trial (completed December 2016, no results posted) and the 853-patient Phase 3 acute mountain sickness trial (completed May 2023, no results posted) remain unpublished in peer-reviewed journals; publication of negative results would weaken the clinical case for T89.
- Nanoparticle and Subcritical Extraction Delivery: Because salvianolic acids and tanshinones have <5% oral bioavailability, preclinical studies are testing chitosan nanoparticles (Zhang et al., 2022) and subcritical water extraction (Kapalavavi et al., 2021). Human trials comparing enhanced-absorption extracts with standard extracts could resolve blood pressure and LDL conflicts (van Poppel et al., 2015).
- Senescence, cGAS-STING, and ESRRG Longevity Pathways: Recent mouse studies show salvianolic acid A blocks cGAS-STING inflammation (Zuo et al., 2024), salvianolic acid B activates cutaneous Nrf2 (Sun et al., 2024), and tanshinone IIA slows liver aging via ESRRG/CYP2E1 (Liu et al., 2024). Human trials measuring senescence biomarkers will determine whether these mechanisms translate clinically.
Conclusion
Danshen (Salvia miltiorrhiza) is a traditional Chinese root botanical containing water-soluble phenolic acids and fat-soluble red quinone compounds that influence blood vessel relaxation, antioxidant enzyme activity, platelet clumping, and tissue scarring. For proactive, longevity-oriented adults evaluating oral supplementation, the human clinical evidence base presents a sharp divide between hospital-based multi-herb or intravenous treatments and standalone oral root extracts.
Among oral single-herb preparations, human evidence reaches a medium level only for relieving male lower urinary tract symptoms and supporting erectile function, where a multicenter randomized trial funded partly by the extract manufacturer demonstrated clear symptom relief. Broader heart, kidney, and stroke recovery claims rest on low-level or conflicted evidence. While large Chinese meta-analyses report improvements in stable angina and kidney filtration, those studies predominantly tested multi-ingredient formulas containing Panax notoginseng and synthetic borneol or hospital intravenous infusions. Conversely, rigorous placebo-controlled trials of oral Danshen extracts in Western and high-altitude settings found no blood pressure reduction, no protection against mountain sickness, and an unexpected increase in harmful low-density cholesterol.
Meanwhile, high-level human drug-interaction evidence confirms that repeated oral Danshen use speeds up the liver and gut breakdown of common prescription drugs, including statins, blood thinners, and calcium channel blockers, while case reports document severe bleeding when combined with warfarin. Consequently, the evidence portrays oral Danshen not as a broadly validated foundational longevity supplement, but as a specialized botanical with targeted male urological utility and substantial medication interaction liabilities.